GUIDE.MRD partners have attended the American Society of Clinical Oncology (ASCO) meeting in Chicago, May 30 -June 3 (https://www.asco.org/annual-meeting)
To all our GUIDE.MRD partners and contributors — thank you for co-creating a shared vision for better follow-up cancer care.
Here is the link to the abstract: https://lnkd.in/esRAwZBx
We have introduced the Ideal Healthcare Pathway for post-treatment cancer care, co-created with patients, clinicians, researchers, and policymakers.
While the ASCO abstract lays the foundation through a clear summary, the full pathway brings that work into practice, across systems, and into the lives of people who need it.
This pathway is a response to real, persistent gaps in follow-up care across Europe, and a first step toward strengthening the role of precision diagnostics.
At its centre is circulating tumour DNA (ctDNA) assays for Minimal Residual Disease (MRD) detection—a tool that can support earlier relapse or recurrence and enable more personalised decisions after treatment with curative intent.
The pathway aims to:
✔️ Reduce unnecessary or burdensome treatments
✔️ Support timely interventions and provide peace of mind
✔️ Offer a shared reference to guide personalised follow-up care
We invite you to explore the abstract — and stay tuned as we bring the full pathway to life. Because better care doesn’t happen in isolation. It’s co-created.
